Fig. 8.

Diminished oligodendrocyte accumulation in demyelinating lesions of PLX5622-treated mice. Infected mice were treated at day 7 p.i. with PLX5622-containing or control feed. Representative images of Olig2 immunostaining in normal appearing WM (NAWM) and WMLs of control-treated mice and WMsL of PLX5622-treated mice at 21 dpi, Scale bars, 100 μm. (A). Quantification of Olig2 staining in WMLs at 14 dpi (B) and in NAWMs and WMLs at 21 dpi (C). Too little NAWM was detected in drug-treated mice at day 21 p.i. to allow quantification. GM: gray matter; WM: white matter. Data in B are representative of three to four mice per group. Data in C show individual mice with four to five mice per group and represent the mean ± SEM, *P < 0.05 by Mann–Whitney U test.